BACKGROUND: We herein report the long-term results of an allogeneic reduced-intensity conditioning (allo-RIC) protocol used in 21 consecutive patients (16 males, median age 56 years, 71% in complete remission) diagnosed with mantle cell lymphoma (MCL). METHODS: The allo-RIC consisted of fludarabine plus melphalan and peripheral blood hematopoietic stem cells (PBSCs) from human leukocyte antigen (HLA)-identical siblings were used in all cases. Median CD34+ infused cells was 5.8 times 10(6)/kg. All patients engrafted promptly. RESULTS: Early toxicity included mild/moderate mucositis (43%), febrile neutropenia (33%) and bacterial infections (19%). With a median follow up of 48 months, four deaths were reported, all due to infections and/or graft-versus-host disease (GVHD), yielding a 3-year cumulative incidence of nonrelapse mortality of 19.5%. Grade III-IV acute GVHD occurred in 15% and chronic GVHD in 78%, being extensive in 39%. The 5-year progression-free survival (PFS) and overall survival (OS) were both 80% (95% CI: 63-97%). Age was the only possible prognostic factor for OS, which was 43% for those aged more than 60 years and 100% for those younger (p < 0.001). CONCLUSIONS: Our data confirm that allo-RIC offers a low toxicity profile and a chance for prolonged long-term disease-free survival in MCL, particularly in younger patients.
BACKGROUND: We herein report the long-term results of an allogeneic reduced-intensity conditioning (allo-RIC) protocol used in 21 consecutive patients (16 males, median age 56 years, 71% in complete remission) diagnosed with mantle cell lymphoma (MCL). METHODS: The allo-RIC consisted of fludarabine plus melphalan and peripheral blood hematopoietic stem cells (PBSCs) from human leukocyte antigen (HLA)-identical siblings were used in all cases. Median CD34+ infused cells was 5.8 times 10(6)/kg. All patients engrafted promptly. RESULTS: Early toxicity included mild/moderate mucositis (43%), febrile neutropenia (33%) and bacterial infections (19%). With a median follow up of 48 months, four deaths were reported, all due to infections and/or graft-versus-host disease (GVHD), yielding a 3-year cumulative incidence of nonrelapse mortality of 19.5%. Grade III-IV acute GVHD occurred in 15% and chronic GVHD in 78%, being extensive in 39%. The 5-year progression-free survival (PFS) and overall survival (OS) were both 80% (95% CI: 63-97%). Age was the only possible prognostic factor for OS, which was 43% for those aged more than 60 years and 100% for those younger (p < 0.001). CONCLUSIONS: Our data confirm that allo-RIC offers a low toxicity profile and a chance for prolonged long-term disease-free survival in MCL, particularly in younger patients.
Authors: I F Khouri; M S Lee; J Romaguera; N Mirza; H Kantarjian; M Korbling; M Albitar; S Giralt; B Samuels; P Anderlini; J Rodriguez; B von Wolff; J Gajewski; F Cabanillas; R Champlin Journal: Ann Oncol Date: 1999-11 Impact factor: 32.976
Authors: Martin Dreyling; Georg Lenz; Eva Hoster; Achiel Van Hoof; Christian Gisselbrecht; Rudolf Schmits; Bernd Metzner; Lorenz Truemper; Marcel Reiser; Hjalmar Steinhauer; Jean-Michel Boiron; Marc A Boogaerts; Ali Aldaoud; Vittorio Silingardi; Hanneke C Kluin-Nelemans; Joerg Hasford; Reza Parwaresch; Michael Unterhalt; Wolfgang Hiddemann Journal: Blood Date: 2004-12-09 Impact factor: 22.113
Authors: I F Khouri; R M Saliba; S A Giralt; M S Lee; G J Okoroji; F B Hagemeister; M Korbling; A Younes; C Ippoliti; J L Gajewski; P McLaughlin; P Anderlini; M L Donato; F F Cabanillas; R E Champlin Journal: Blood Date: 2001-12-15 Impact factor: 22.113
Authors: Georg Lenz; Martin Dreyling; Eva Hoster; Bernhard Wörmann; Ulrich Dührsen; Bernd Metzner; Hartmut Eimermacher; Andreas Neubauer; Hannes Wandt; Hjalmar Steinhauer; Sonja Martin; Else Heidemann; Ali Aldaoud; Reza Parwaresch; Joerg Hasford; Michael Unterhalt; Wolfgang Hiddemann Journal: J Clin Oncol Date: 2005-01-24 Impact factor: 44.544
Authors: Emma Morris; Kirsty Thomson; Charles Craddock; Prem Mahendra; Donald Milligan; Gordon Cook; Graeme Murray Smith; Anne Parker; Steve Schey; Rajesh Chopra; Christopher Hatton; Jane Tighe; Anne Hunter; Karl Peggs; David Linch; Anthony Goldstone; Stephen Mackinnon Journal: Blood Date: 2004-08-10 Impact factor: 22.113
Authors: Michael B Maris; Brenda M Sandmaier; Barry E Storer; Thomas Chauncey; Monic Jain Stuart; Richard T Maziarz; Edward Agura; Amelia A Langston; Michael Pulsipher; Rainer Storb; David G Maloney Journal: Blood Date: 2004-08-10 Impact factor: 22.113
Authors: Michael R Bishop; Jeannie Whit-Shan Hou; Wyndham H Wilson; Seth M Steinberg; Jeanne Odom; Kathleen Castro; Claude Kasten-Sportes; Juan Gea-Banacloche; Donna Marchigiani; Ronald Gress; Daniel H Fowler Journal: Biol Blood Marrow Transplant Date: 2003-03 Impact factor: 5.742
Authors: Pashna N Munshi; Mehdi Hamadani; Ambuj Kumar; Peter Dreger; Jonathan W Friedberg; Martin Dreyling; Brad Kahl; Mats Jerkeman; Mohamed A Kharfan-Dabaja; Frederick L Locke; Mazyar Shadman; Brian T Hill; Sairah Ahmed; Alex F Herrera; Craig S Sauter; Veronika Bachanova; Nilanjan Ghosh; Matthew Lunning; Vaishalee P Kenkre; Mahmoud Aljurf; Michael Wang; Kami J Maddocks; John P Leonard; Manali Kamdar; Tycel Phillips; Amanda F Cashen; David J Inwards; Anna Sureda; Jonathon B Cohen; Sonali M Smith; Carmello Carlo-Stella; Bipin Savani; Stephen P Robinson; Timothy S Fenske Journal: Bone Marrow Transplant Date: 2021-08-20 Impact factor: 5.483